MENOPAUSAL HORMONE REPLACEMENT THERAPY IN PREVENTION MENOPAUSAL THERAPY
Keywords:
Key words: estrogen replacement therapy, menopause, osteoporosis.Abstract
Summary: Postmenopausal women suffer hip fractures caused by osteoporosis that develops primarily as a consequence of the low estrogen levels of menopause. Calcium supplementation, although probably important before menopause, cannot stop bone loss alone in the perimenopausal and postmenopausal phases. Estrogen replacement therapy remains the treatment of choice. As little as 0.625 mg of conjugated estrogens can inhibit bone loss. Oral contraceptives also have a beneficial effect on bone density. Although fluoride therapy can increase bone mass, objectionable side effects rule out its use.
References
References
Kanis JA, Cooper C, Rizzoli R, Reginster JY, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2019;30(1):3–44.CAS PubMed Article PubMed Central Google Scholar
Hernlund E, Svedbom A, Ivergard M, Compston J. Osteoporosis in the European Union: medical management, epidemiology and economic burden. Arch Osteoporos. 2013;8:136.CAS PubMed PubMed Central Article Google Scholar
Sowers MR, Zheng H, Greendale GA, Neer RM, Cauley JA, Ellis J, et al. Changes in bone resorption across the menopause transition: effects of reproductive hormones, body size, and ethnicity. J Clin Endocrinol Metab. 2013;98(7):2854–63.CAS PubMed PubMed Central Article Google Scholar
Torgerson DJ, Bell-Syer SE. Hormone replacement therapy and prevention of vertebral fractures: a meta-analysis of randomised trials. BMC Musculoskelet Disord. 2001;2:7.CAS PubMed PubMed Central Article Google Scholar
Torgerson DJ, Bell Syer SE. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA. 2001;285(22):2891–7.CAS PubMed Article PubMed Central Google Scholar
Greenspan SL, Resnick NM, Parker RA. Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial. JAMA. 2003;289(19):2525–33.CAS PubMed Article PubMed Central Google Scholar
Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPI. JAMA. 1996;276(17):1389–96.
Barrett-Connor E, Wehren LE, Siris ES, Miller P, Chen YT, Abbott TA 3rd, et al. Recency and duration of postmenopausal hormone therapy: effects on bone mineral density and fracture risk in the National Osteoporosis Risk Assessment (NORA) study. Menopause. 2003;10(5):412–9.
PubMed Article PubMed Central Google Scholar
Shevde NK, Bendixen AC, Dienger KM, Pike JW. Estrogens suppress RANK ligandinduced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression. Proc. Natl. Acad. Sci. USA. 2000;97:7829–7834. [PMC free article] [PubMed] [Google Scholar]
Hofbauer LC, et al. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J. Bone Miner. Res. 2000;15:2– [PubMed] [Google Scholar]
Riggs BL, Khosla S, Melton LJ., III A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J. Bone Miner. Res. 1998;13:763–773. [PubMed] [Google Scholar]
Зарипова Д.Я., Негматуллаева М.Н. Влияние магний дефицитного состояния и дисбаланса стероидных гормонов жизнедеятельности организма женщины. Тиббиётда янги кун 2019; 3 (27) Стр- 14-18.
Зарипова Д.Я., Негматуллаева М.Н.,Туксанова Д.И. Роль Алеандроновой кислоты (Осталон) в лечении перименопаузального остеопороза. Доктор ахборотномаси 2019; 3 Стр- 51-55.
Зарипова Д.Я., Туксанова Д.И. Опыт применения трансдермального препарата Лензетто у женщин перименопаузального возраста с сопутствующими заболеваниями 2(30/2) 2020 г. Стр-286.
Xатамова М.Т., Солиева Н.К. Актуальные особенности хронического пиелонефрита у женщин детородного возраста. Тиббиётда янги кун 3 (27) 2019.
